
FDA Expands Benralizumab Use for Asthma to Kids Over Age 6
Benralizumab, marketed as Fasenra, has been approved by the US FDA for treating asthma in children aged 6 years and older with severe eosinophilic asthma. Originally approved in 2017 for patients aged 12 and older, the drug has shown consistent safety and tolerability in younger patients. AstraZeneca announced the expanded indication on April 11, with…